CSL share price lifts on half-year earnings beat

CSL has delivered a messy half-year result but appears to have beaten the market's expectations…

| More on:
a man sits at his desk wearing a business shirt and tie and has a hearty laugh at something on his mobile phone.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares are rising after the release of its half-year results
  • The biotherapeutics giant delivered an 'untidy' result according to Goldman Sachs
  • However, it appears to have been ahead of expectations

The CSL Limited (ASX: CSL) share price is edging higher on Tuesday morning.

At the time of writing, the biotherapeutics giant's shares are up 0.5% to $306.36.

Why is the CSL share price rising?

The CSL share price is rising today after the market responded relatively positively to the release of the company's half-year results.

For the six months ended 31 December, CSL reported a 19% increase in revenue to US$7,183.5 million and a 10% lift in net profit after tax before amortisation (NPATA) in constant currency to US$1,957 million.

This was driven partly by a five-month contribution from Vifor Pharma, strong growth in immunoglobulin and albumin sales, and record levels of plasma collections.

This allowed the CSL board to lift its interim dividend by 2.9% to US$1.07 per share.

Looking ahead, management has reaffirmed its guidance for FY 2023 NPATA in the range of approximately US$2.7 billion to US$2.8 billion at constant currency.

How does this compare to expectations?

Analysts at Goldman Sachs have had a quick look at the result and given their verdict.

While the broker described the result as "untidy", it acknowledges that it appears "in-line to slightly ahead".

This appears to explain why the CSL share price is rising this morning. It commented:

Juggling various profit lines, we expect the market to focus on a combination of: 1) statutory NPAT (-8% YoY, but flat at constant currency), both seemingly in-line with consensus; and 2) NPATA (+2% YoY, but +10% at constant currency), which appears +3% ahead. CSL may be running slightly ahead of FY guidance on the NPATA adjustments but this is not clear, and we will await further colour on the call. In any case, FY23 guidance for NPATA of $2.7-2.8bn has been reiterated, which we also presume to mean that the prior NPAT guidance remains in effect.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Telix Pharmaceuticals share price sinks 5% on giant debt deal

This high-growth drug developer is turning to debt for its next wave of expansion.

Read more »

Lab worker puts hands in the air and dances around
Healthcare Shares

Guess which ASX healthcare stock just rocketed 46% on major news!

Investors are sending this ASX healthcare stock flying higher on Wednesday. But why?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Earnings Results

Polynovo share price surges after 57% revenue gain in FY24

Global sales continue to grow for Polynovo.

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Healthcare Shares

If you invested $5,000 in this ASX pharmaceuticals stock a year ago, you'd have $34,711 now!

Just how lucky have investors been with this stock?

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Should I buy CSL shares now for their 'steadily growing' dividends?

CSL has increased its interim and final dividend payouts for four years running now.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX healthcare stock is surging on big FDA news

The update is a critical milestone for the company.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Up 308% in 6 months, why is the Mesoblast share price tumbling today?

The Mesoblast share price is taking a tumble on Monday. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

This ASX 200 med-tech stock has no debt, pays dividends and is growing at 30% per year!

This stock is delivering very healthy growth.

Read more »